Maprium enables pharmaceutical and biotech companies to design, manage and govern Managed Access Programs globally.
As innovation accelerates, access remains the primary bottleneck for patients. Managed Access — also known as Expanded Access, Compassionate Use, Named Patient and Post-Trial Access — is now a strategic, regulatory and ethical requirement. Yet many organisations still rely on fragmented tools, manual processes and vendor-owned systems to manage complex global programmes.
Maprium provides the digital infrastructure for Managed Access.
Our platform embeds regulatory, medical and safety requirements into configurable, country-aware workflows, giving sponsors full visibility, control and auditability across programmes and geographies. Unlike service-led models, Maprium is sponsor-owned and vendor-agnostic, enabling companies to retain ownership of their data, governance and long-term access strategy while working with preferred partners.
Built specifically for regulated life sciences environments, Maprium supports equitable, compliant and scalable access to medicines — without compromising control or data integrity.
Built for compliance. Built for scale. Built for pharma.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
What industry is Maprium in?
Maprium operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Maprium based?
Maprium is headquartered in London, United Kingdom.
Find investors for your startup like Maprium
Gritt sends AI-personalised outreach to each investor — from your Gmail
